Clinical Trials Logo

Osteochondral Lesion of Talus clinical trials

View clinical trials related to Osteochondral Lesion of Talus.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05476692 Not yet recruiting - Clinical trials for Osteochondral Lesion of Talus

Clinical Outcome of Surgical Treatment for Osteochondral Lesions of the Talus

Start date: October 1, 2022
Phase:
Study type: Observational

Assess clinical and radiological outcome of the various surgical techniques for treatment of osteochondral lesions of the talus

NCT ID: NCT04475341 Not yet recruiting - Clinical trials for Osteochondral Lesion of Talus

Osteochondral Lesions Under 15mm2 of the Talus; is Iliac Crest Bone Marrow Aspirate Concentrate the Key to Success?

OUTBACK
Start date: September 1, 2020
Phase: N/A
Study type: Interventional

Osteochondral defects (OCDs) of the talus have a significant impact on the quality of life of patients. When OCDs are of small nature (up to 15 mm in diameter), and have failed conservative management, surgical intervention may be necessary. For small cystic defects the current treatment is an arthroscopic bone marrow stimulation (BMS) procedure, during which the damaged cartilage is resected and the subchondral bone is microfractured (MF), in order to disrupt intraosseous blood vessels and thereby introduce blood and bone marrow cells into the debrided lesion, forming a microfracture fibrin clot, which contains a dilute stem cell population from the underlying bone marrow. This procedure has been reported to have a 75% successful long-term outcome. Recently, the additional use of biological adjuncts has become popular, one of them being bone marrow aspirate concentrate (BMAC) from the iliac crest. BMAC consists of mesenchymal stem cells, hematopoietic stem cells and growth factors, which may therefore theoretically improve the quality of subchondral plate and cartilage repair. The current evidence for treating talar OCDs with BMS plus BMAC is limited and heterogeneous. It is unclear to what extent the treatment of talar OCDs with BMS plus BMAC is beneficial in comparison to BMS alone.